Agenus’ Post

Dr. Mims, a renowned medical oncologist and associate professor at The Ohio State University Comprehensive Cancer Center, explores the potential of emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, in heavily pretreated patients with FLT3-mutated relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. The phase 1/2a TakeAim Leukemia trial (NCT04278768) is currently assessing emavusertib's efficacy in these challenging cases. https://lnkd.in/dpdNT5bH

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Another important publication demonstrating Fortrea's leadership across oncology clinical development. Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

📚💡❗ARV-471 Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials

As ESMO - European Society for Medical Oncology 2024 concludes, we’re highlighting the top companies that made a mark in oncology. From innovative treatments to impactful clinical trials, these leaders have been pivotal in advancing cancer research and therapies. For more detailed insights, check out LARVOL CLIN here 🔗 https://bit.ly/47krWpH. #ESMO24 #Oncology #ClinicalTrials #CancerResearch #LARVOL #CancerData

Breast cancer is a leading cause of mortality and morbidity worldwide. This article reviews the current landscape of neoadjuvant therapy for HR+/HER2- breast cancer, focusing on #biomarkers for decision making, and exploring next steps of #clinicalresearch in this therapeutic space. #oncologyclinicaltrials